Obezite

Year 2007, Volume: 1 Issue: 2, 107 - 116, 15.07.2007

Reyhan Ersoy

Abstract

Obezite vücut yağ oranında artış olarak tanımlanan bir hastalıktır. Obezite prevalansı geçen birkaç dekadda dramatik olarak artış göstermiştir. Obezite diyabetes mellitus, hipertansiyon, dislipidemi ve koroner arter hastalığının da bulunduğu kardiyometabolik hastalıklar için önemli bir risk faktörüdür ve tedavi edilmelidir. Bu derlemede obezite tanısı, epidemiyolojisi, etiyopatogenezi ve tedavi yaklaşımları gözden geçirilmiştir.

Abstract
Obesity is a disorder of body composition defined by excess of body fat. Its prevalence has increased dramatically over the past several decades. Obesity is an important risk factor for
ardiometabolic diseases, including diabetes mellitus, hypertension, dyslipidemia, and coronary hearth disease and should be treated. In this article, diagnosis, epidemiology, etiopathogenesis and treatment of obesity was reviewed.

Keywords

Obezite, adipoz doku, enerji harcanması, tedavi

References

• 1. World Health Organization: Obesity: Preventing and Managing the Global Epidemic Report of a WHO Consultation on Obesity. Geneva, World Health Organ Tech Rep Ser. 2000;894:1-253.
• 2. National Institutes of Health, National Heart, Lung, and Blood Institute: Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-in evidence report. Obes Res 1998;6(Suppl 2):51S-209S.
• 3. Duerenberg P, Weststrate JA, Seidell JC. Body mass index as a measure of body fatness: Age-and sex-specific prediction formulas. British J Nutr 1991;65:105-14.
• 4. World Health Organization Expert Committee: Physical Status: The Use and Interpretation of Anthropometry. WHO Technical Report Series no. 854. Geneva, World Health Organization, 1995.
• 5. Han TS, van Leer EM, Seidell JC, Lean MEJ. Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. British Med J 1995;311:1401-5.
• 6. Lean MEJ, Han TS, Morrison CE. Waist circumference indicates the need for weight measurement. British Med J. 1995;311:158-61.
• 7. Klein S, Allison DB, Heymsfield SB, et al. Waist circumference and cardiometabolic risk. Diabetes Care, 2007;30:1647-51.
• 8. Jebb SA. Vücut Bileşiminin Ölçülmesi: Laboratuardan Kliniğe. Kopelman PG, Stock MJ, editörler. Klinik Ob-ezite. 1. Baskı. İstanbul: AND Yayıncılık; 2000. s.18-49
• 9. Seidell JC, Deerenberg I. Obesity in Europe: Prevalence and consequences for use of medical care. Pharmacoeconomics 1994;5 (Suppl 1):38-44.
• 10. National Institute of health. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults. National Institute of health Obes Res 1998;6:464.
• 11. Kuczmarski R, Flegal K, Campbell S, Johnson C. Increasing prevalence of overweight among US adults: The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA 1994;205-11.
• 12. Molarius A, Seidel JC, Sans S, Toumilehto J, Kuulasmaa K. Varying sensitivity of wast action levels to identify subjects with overweight or obesity in 19 populations of the WHO MONICA Project. J Clin Epidemiol 1999;52:1213-24
• 13. Satman İ, Şengül AM, Uygur S, et al. Population based study of diabetes and risk characteristics in Turkey: results of the Turkish diabetes epidemiology study (TURDEP). Diabetes Care 2002;25:1551-6.
• 14. Onat A, Yıldırım B, Çetinkaya A, et al. Erişkinlerimizde Obezite ve santral Obezite göstergeleri ve ilişkileri: 1990-98’de düşündürücü obezite artışı erkeklerde daha belirgin. Türk Kardiyoloji Arşivi 1999;27:209-17.
• 15. Hatemi H, Turan N, Arık N, Yumuk V. Türkiye Obezite ve Hipertansiyon taraması sonuçları (TOHTA). Endokrinde Yönelişler Dergisi 2002;11:1-15.
• 16. Hellerstein MK, Parks EJ. Obesity and Overweight. In: Gardner DG, Shobeck D; eds. Greenspan’s Basic and Clinical Endocrinology. 8th ed. New York; McGrawHill; 2007. p.796-816
• 17. Beales P, Kopelman P, Vijayaraghavan S, Hitman GA. The molecular genetics of obesity. In: Bray G, Ryan DH. eds. Molecular Genetic Aspects of Obesity, Pennington Center Nutrition Series. Baton Rouge, LA: Louisiana State Press; 1996. p.534-45.
• 18. Wadden AT, Stunkard AJ, editörler. Obezite Tedavisi El Kitabı. Vücut ağırlığının regülasyonu: Nöral, Endokrin ve Otokrin mekanizmalar. 1. Baskı. İstanbul: AND Yayıncılık; 2003. s.19-41.
• 19. Orhan Y. Şişmanlık. Sencer E (editör) Endokrinoloji, Metabolizma ve Beslenme Hastalıkları. 1. Baskı. İstanbul: Nobel Tıp Kitapevleri; 2001. s.716-33.
• 20. Stevens J, Cai J, Pamuk ER, Williamson DF, Thun MJ, Wood JL. The effect of age on the association between body-mass index and mortality N Engl J Med 1998;338:1-7.
• 21. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body-mass index and mortality in a prospective cohort of U.S. adults N Engl J Med 1999;341: 1097-105.
• 22. Oranzo JA, Scott JG. Diagnosis and treatment of obesity in Adults: An Applied Evidence-Based Review. J Am Board Fam Pract 2004;17:359-69.
• 23. Low AK, Bauldin MJ, Sumrall CD, Loustalot FV, Land KK. A Clinician’s approach to medical management of obesity. Am J Med Sci 2006;331:175-82.
• 24. Collazo-Clavell ML. Safe and effective management of the obese patient. Mayo Clin Proc 1999;74:1255-9.
• 25. Lau DCW, Douketis JD, Morrison KM, Hramiak IM, Sharma AM. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children (summary). CMAJ 2007;176 (8 Suppl):1-13.
• 26. Gökcel A, Gümüldürlü Y. Evaluation of the safety and efficacy of sibutramine, orlistat, and metformine in the treatment of obesity. N Eng J Med 2003;348:2074-81